News Article
Mar 9, 2017
Iain Dukes joins the ReViral Board

London, UK, 9th March 2017 - ReViral are proud to announce that Iain Dukes has joined the ReViral Board.

ReViral Ltd, a company, focused on the discovery and development of breakthrough products for the treatment of respiratory syncytial virus, announced today the appointment of Iain Dukes to the company’s Board of Directors.

“Iain is an outstanding leader in our industry, and I am delighted to welcome him to our Board,” said Eddy Littler, Chief Executive Officer of ReViral. “Iain joins our team during an exciting time for the company, with our programme RV521, in phase 1 clinical trials. Iain brings a wealth of industry knowledge and expertise which will be an invaluable asset to ReViral as we advance the Company.”

Iain D. Dukes, D.Phil., is a Venture Partner with OrbiMed. Iain also serves on the Board of Lion Biotechnologies. Recently Iain was a Senior Vice President, Business Development & Licensing Merck where he oversaw all licensing deals for Merck Research Laboratories, including external research, out-licensing, regional deals and academic alliances. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, he served as vice president of External Research and Development at Amgen. He has also held positions as president and CEO of Essential Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. Degree from the University of Oxford where he also received a B.A. in Jurisprudence.

“Iain’s business development expertise and leadership experience in the pharmaceutical industry will further strengthen our Board’s broad skillset,” said Ken Powell Chairman of the Board of ReViral. “I am confident that Iain will make significant contributions to the ReViral Board, which will translate into a positive impact for the company.”

“It’s a pivotal time for therapies for RSV and ReViral has built an innovative pipeline that’s well positioned to address the growing unmet medical need,” said Dukes. “I admire the company's achievements since its inception in 2011, and I very much look forward to joining the current Board of Directors in developing ReViral into the foremost leader in RSV therapy.”